Si desea más información sobre Eisai Co., Ltd., visite nuestro sitio web http://www.eisai.com.  

Bibliografía  

 1. EUCAN 2015. Available at: http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35. Accessed: November 2016

Include reference indicated in comments.

 2. J. Capdevilla et al . Consensus on the management of Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer: Spanish Task Force for Thyroid Cancer on Behalf of Spanish Societ of Endocrinology (SEEN) and Spanish Rare Cancer Working Group (GETHI)

 3. María Pilar Salvador Egea, et al . Differentiated Thyroid Cancer in Navarra (Spain) : Historic Cohort Results (1987-2003). ISRN Oncol. 2011; 2011: 560503.

 4. SmPC Lenvima (lenvatinib) (updated Oct 2016) Available at: https://www.medicines.org.uk/emc/medicine/30412 Accessed: November 2016

 5. Sacks W, Braunstein G. Clinically meaningful endpoints in the evolving treatment paradigm for radioactive iodine-refractory differentiated thyroid cancer. Expert Review of Endocrinology & Metabolism. Early online, 1-8 (2015).

 6. Durante 2006. J. Clin. Endo & Met. 91(8):2892-2899

 7. Schlumberger M, Tahara M, et al . Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM, 2015; 372: 621-630. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1406470 Accessed: November 2016

 8. Matsui J, et al . E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-671

 9. SmPC Kisplyx (lenvatinib), (updated September 2016). Available at: https://www.medicines.org.uk/emc/medicine/32335 . Accessed: November 2016

 10. National Cancer Institute at the National Institute of Health. Thyroid Cancer Treatment. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/Patient/page1/AllPages#1 [http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/Patient/page1/AllPages ]. Accessed: November 2016

CONTACTO: Consultas de los medios de comunicación: Eisai, Cressida Robson/ Ben Speller, +44 7908 314 155/+44 7908 409 416, Cressida_Robson@eisai.net/ Ben_Speller@eisai.net | Tonic Life Communications: Alex Davies / CallumHaire, + 44 7716 324 722 / +44 7867 429 637, Alex.Davies@toniclc.com /Callum.Haire@toniclc.com